MimeCure raises €3M for inhaled therapy targeting chronic lung diseases
What's the deal? MimeCure, a Dutch biotech spun out of the University of Groningen, has raised €3M to develop an inhaled regenerative therapy for chronic lung diseases. The round is led by Addington Investment Group, with Apsara InvestmentsDealroom has a profile for this one. Try Dealroom → as co-investor. The funds will help MimeCure complete preclinical work on its lead candidate, MC002, and prepare for first-in-human clinical studies.
MC002 is designed to be inhaled directly into the lungs, combining two effects in one treatment: reducing scar tissue formation and activating the lung's natural repair capacity. It targets Idiopathic Pulmonary Fibrosis (IPF) and Chronic Obstructive Pulmonary Disease (COPD).
Why now? IPF affects an estimated 2.5 million people worldwide and carries a grim prognosis — untreated patients have a median survival of roughly three years. Current antifibrotic treatments can only slow the disease, not reverse it. There is no approved therapy that restores damaged lung tissue, leaving a significant unmet medical need.
What could go wrong? MimeCure is still in the preclinical stage, meaning years of clinical trials lie ahead before any product could reach patients. Inhaled biologics face complex manufacturing and delivery challenges. And the leap from promising lab results to human efficacy is notoriously difficult — most drug candidates fail in clinical development.
A €3M raise, while meaningful for an early-stage biotech, is modest. MimeCure will likely need substantially more capital to fund clinical trials.
The signal: MimeCure's €3M raise underscores a persistent gap in pulmonary fibrosis treatment — with 2.5 million IPF patients worldwide and no approved therapy that reverses lung damage, even modest preclinical-stage rounds can attract backers betting on outsized unmet need. The round was co-led by Apsara Investments, an investment fund backing an early bet on inhaled regenerative medicine, a niche where few competitors have advanced beyond the lab.
Read more: 3d-pxc.com
